Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.400
+0.180 (14.75%)
At close: Jul 22, 2025, 4:00 PM
1.430
+0.030 (2.14%)
After-hours: Jul 22, 2025, 7:59 PM EDT

Company Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.

Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.

It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.
Cardiol Therapeutics logo
CountryCanada
Founded2017
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees18
CEODavid Elsley

Contact Details

Address:
2265 Upper Middle Road East, Suite 602
Oakville, ON L6H 0G5
Canada
Phone289 910 0850
Websitecardiolrx.com

Stock Details

Ticker SymbolCRDL
ExchangeNASDAQ
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyCAD
CIK Code0001702123
CUSIP Number14161Y200
ISIN NumberCA14161Y2006
SIC Code2836

Key Executives

NamePosition
David G. Elsley MBAPresident, Chief Executive Officer and Director
Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBAChief Financial Officer, Corporate Secretary and Director
Bernard Lim B.Sc.Chief Operating Officer
Dr. Andrew Warwick Hamer M.D.Chief Medical Officer and Head of Research and Development
Trevor BurnsInvestor Relations
John A. Geddes BSCPT, MBAVice President of Corporate Development

Latest SEC Filings

DateTypeTitle
Jul 22, 20256-KReport of foreign issuer
May 29, 20256-KReport of foreign issuer
May 27, 20256-KReport of foreign issuer
May 14, 20256-KReport of foreign issuer
Apr 29, 20256-KReport of foreign issuer
Apr 28, 20256-KReport of foreign issuer
Apr 16, 20256-KReport of foreign issuer
Apr 1, 20256-KReport of foreign issuer
Mar 31, 202540-FFiling
Mar 14, 20256-KReport of foreign issuer